Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 17Urinary Bladder Neoplasms 3Neoplasms 2Disease 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 3Trastuzumab 2Nivolumab 2tucatinib 1regorafenib 1pertuzumab 1niraparib 1milademetan 1dostarlimab 1cobimetinib 1brigimadlin 1atezolizumab 1alectinib 1Vemurafenib 1Tomography, X-Ray Computed 1Ramucirumab 1Radiation 1Positron-Emission Tomography 1Paclitaxel 1Magnetic Resonance Imaging 1HhAntag691 1Fulvestrant 1Erlotinib Hydrochloride 1Clinical Trials, Phase II as Topic 1Carboplatin 1Brachytherapy 1Antibodies 1AZD9833 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Positron-Emission Tomography × Genitourinary × Clear all
NCT00924027 2025-09-05

A Study of Patients Receiving High-Dose Rate Brachytherapy

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
43 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Biliary Tract Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡